Orchestra BioMed Holdings (OBIO) Cash from Investing Activities (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Cash from Investing Activities for 5 consecutive years, with $10.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 20.62% year-over-year to $10.3 million; the TTM figure through Mar 2026 stood at -$29.6 million (down 246.45% YoY), while the FY2025 annual figure was -$26.9 million, down 305.83% from the prior year.
• Cash from Investing Activities climbed to $10.3 million in Q1 2026 per OBIO's latest filing, from -$17.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.2 million in Q4 2023 and bottomed at -$63.4 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$3.4 million across 5 years, with a median of $557000.0 in 2024.
• On a YoY basis, Cash from Investing Activities climbed as much as 5879.91% in 2023 and fell as far as 92514.89% in 2023.
• Orchestra BioMed Holdings' Cash from Investing Activities stood at -$63.4 million in 2022, then surged by 152.31% to $33.2 million in 2023, then tumbled by 111.32% to -$3.8 million in 2024, then plunged by 371.94% to -$17.7 million in 2025, then surged by 158.25% to $10.3 million in 2026.
• Business Quant data shows OBIO's Cash from Investing Activities at $10.3 million in Q1 2026, -$17.7 million in Q4 2025, and -$38.6 million in Q3 2025.